Myomo, Inc.

MYOMO maintains a current ratio of 2.73, supported by $11.4 million in cash and equivalents against $2.7 million in short-term debt, resulting in a low debt-to-equity ratio of 0.3. However, the company faces high dilution risk, evidenced by a diluted share count of 42.3 million versus 38.6 million basic shares, and operates with a negative free cash flow of $2.5 million in Q1 2026. The market capitalization stands at $43.3 million, implying a price-to-book ratio of 4.81, while the enterprise value-to-revenue multiple is 0.74, reflecting the market's pricing of its pre-profitability status.

Profitability remains negative, with a return on equity of -1.73 and a return on assets of -0.42, driven by an operating loss of $3.2 million on $10.1 million in revenue. The gross profit of $6.9 million indicates a gross margin of approximately 68%, but operating expenses, including $597,248 in stock-based compensation and significant R&D and clinical costs, outweigh this contribution. The company reports an accumulated deficit of $121.7 million, highlighting the historical capital intensity required to reach its current commercialization stage.

Revenue is derived from contracts with customers, primarily through the sale of the MyoPro device for stroke rehabilitation. The company targets a market of approximately 3.8 million people with moderate to severe upper extremity impairment post-stroke. Geographic and segment-specific revenue breakdowns are not detailed in the available data, but the focus remains on the medical device segment within the healthcare equipment industry.

Growth trajectory is characterized by persistent net losses, with Q1 2026 net income of -$3.0 million compared to -$3.5 million in the prior year period, indicating a slight improvement in net loss magnitude. Operating cash flow used $2.2 million in Q1 2026, an improvement from $2.7 million used in the same period last year. The company continues to invest in software development and equipment, with capital expenditures of $327,807 in Q1 2026, supporting its long-term commercialization efforts.

Key risks include high dilution potential from warrant exercises and potential conversions by Avenue Capital Management, as well as regulatory exposure to CMS coverage requirements for Medicare Advantage plans. Liquidity risk is assessed as low due to adequate cash reserves, but the company explicitly states its reliance on possible public or private equity offerings to fund future operations. The stock price recently fell below $1.00, triggering US continued-listing minimum-bid threshold concerns, which poses a near-term delisting risk if not resolved.

Recent filings highlight the company's cash flow dynamics and liquidity position, with no new financing activities in Q1 2026. Analyst sentiment is mixed, with a mean price target of $4.42 and a median of $3.00, suggesting potential upside from current levels, but the mean recommendation of 2.00 (Buy) is based on five buy ratings with no strong buys or holds. The company continues to navigate the challenges of commercializing a specialized medical device in a regulated environment.

Myomo, Inc. (MYO) has undergone a comprehensive revision of its AI-driven analytical profile, marking a significant update to how the company’s business fundamentals and market position are interpreted. The most material change involves the introduction of a specific market share metric, which was previously unquantified, now recorded at approximately 0.0000239%. This new data point, alongside substantial rewrites to the company’s business summary, narrative, and conclusion, indicates a shift from qualitative assessment to a more defined, albeit small, quantitative market presence. The revision of the AI analysis narrative and business summary suggests a recalibration of Myomo’s strategic positioning within its industry. With a similarity score of only 0.046 for the narrative and conclusion, and 0.268 for the business summary, the updated analysis diverges significantly from prior assessments. This implies that recent developments or data inputs have prompted a fundamental re-evaluation of the company’s operational context and future outlook, moving away from previous assumptions. Key takeaways from the analysis have also been completely overhauled, with seven new insights added and seven removed. This turnover in key takeaways reflects a dynamic reassessment of the factors driving Myomo’s performance and risks. The inclusion of the market share percentage provides a concrete benchmark for the company’s competitive standing, offering investors a clearer, albeit modest, view of its footprint in the broader market. Despite these analytical updates, Myomo remains a niche player with no analyst coverage, index membership, or disclosed officers in the current dataset, though it maintains 18 top holders. The absence of watcher signals or cross-source conflicts suggests that these changes are internal to the analytical framework rather than driven by external market events or regulatory filings. For investors, the significance lies in the enhanced granularity of the data, which now supports a more precise, data-backed understanding of Myomo’s market share and business trajectory.

Revenue grew at a 30.1% CAGR from FY2023 to FY2025, demonstrating strong top-line expansion momentum.

Analysts project 368.9% upside to a mean price target of $4.42, signaling significant undervaluation.

Free cash flow improved by 71.4% year-over-year in FY2025, indicating better operational efficiency.

The company maintains a low leverage band with a debt-to-equity ratio of 1.24.

Liquidity risk is assessed as low, supported by a current ratio of 3.30.

Dilution risk is rated high, threatening existing shareholder value through potential equity issuance.

The company reported a net loss of $15.6 million in FY2025, reflecting persistent unprofitability.

Free cash flow was negative $16.3 million in FY2025, indicating continued cash burn.

Revenue $10.1M; Operating income -$3.2M.

• ▍Revenue $10.1M
• ▍Operating income -$3.2M
• ▍Net margin -29.8%

Revenue $29.6M; Operating income -$11.6M.

• ▍Revenue $29.6M
• ▍Operating income -$11.6M
• ▍Net margin -39.8%

Revenue $40.9M; Operating income -$14.4M.

• ▍Revenue $40.9M
• ▍Operating income -$14.4M
• ▍Net margin -38.1%

Revenue $32.6M; Operating income -$6.2M.

• ▍Revenue $32.6M
• ▍Operating income -$6.2M
• ▍Net margin -19.0%

Revenue $32.6M; Operating income -$6.2M.

• ▍Revenue $32.6M
• ▍Operating income -$6.2M
• ▍Net margin -19.0%

Revenue $19.2M; Operating income -$8.2M.

• ▍Revenue $19.2M
• ▍Operating income -$8.2M
• ▍Net margin -42.3%

Revenue $19.2M; Operating income -$8.2M.

• ▍Revenue $19.2M
• ▍Operating income -$8.2M
• ▍Net margin -42.3%